Pathologic and molecular biologic diagnosis of multicentric hepathocellular carcinoma and treatment for such carcinoma
Pathologic and molecular biologic diagnosis of multicentric hepathocellular carcinoma and treatment for such carcinoma
批准号:
10671211
负责人:
KINOSHITA Hiroaki
金额:
$1.34万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We evaluated clinicopathologic criteria for multicentric hepatocellular carcinoma (HCC) and identified risk factors for such carcinogenesis. One kind of multicentric HCC had at least one tumor consisting of well differentiated HCC, together with moderately or poorly differentiated HCC located in a separate region. The other kind had an area of well differentiated component around HCC with less differentiated in all occurrence. The risk factors include past history of blood transfusion, high value of 15-min indocyanine green retension test, high alanine aminotransferase activity, hyper-bilirubinemia, hepatitis C virus infection with or without past infection of hepatitis B virus. The risk increases as the progress in active hepatitis and hepatic fibrosis. Analysis of patterns of X-chromosome inactivation was useful for differentiation of multicentric carcinogenesis from intrahepatic metastasis. The cumulative survival rate was significantly higher in patients with multicentric HCCs than in patients with intrahepatic metastasis. The risk factors for multicentric reccurrence include low platelet count. The strategy for treatment for HCC should be based on the potential for hepatocarcinogenesis estimated by such risk factors.
期刊论文(45)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Tamori A, et al: "Possible contribution to hepatocarcinogenesis of X tronscipt of hepatitis B virus in Japanese patients with hepatitis C virus"Hepatology. 29. 1429-1434 (1999)
Tamori A 等人:“日本丙型肝炎病毒患者中乙型肝炎病毒 X 片段对肝癌发生的可能贡献”肝病学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Shuto T. et al: "Hyperplastic foci as a prognostic factor atten resectim of hepatocelluon carcinoma"Hepatogaotroenterology. 46. 2439-2441 (1999)
Shuto T. 等人:“增生性灶作为肝细胞癌切除术的预后因素”Hepatogaotroenterology。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Shuto T, et al: "Post-opexative blood tests and multicentric recurrence ofhepatucelliilan"Hepatogaotroenterology. 46. 2545-2546 (1999)
Shuto T 等人:“术后血液检查和肝细胞的多中心复发”Hepatogaotroenterology。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kubo S, Hirohashi K, Tanaka H, et al.: "Strategy for hepatocellular carcinoma according to the state of hepatitis virla infection"Gastrointestinal Surg. 21. 425-430 (1998)
Kubo S,Hirohashi K,Tanaka H,等:“根据肝炎病毒感染状态的肝细胞癌策略”胃肠外科。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kubo S, et al: "Clinicul significamce of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma"Camcer. 86. 793-798 (1999)
Kubo S 等人:“丙型肝炎病毒相关肝细胞癌患者既往乙型肝炎病毒感染的临床意义”Camcer。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 45 条
DEVELOPMENT OF PORTAL OCCLUSION AS MULTIDICPLINARY TREATMENT AND ITS CLINICAL USE FOR ADVANCED HEPATOCELLULAR CARCINOMA
-
批准号:08671473
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.22万
-
财政年份:1996
-
负责人:KINOSHITA Hiroaki
-
依托单位:
Experimental study about extension of surgical indications of liver resection by percutaneous transhepatic portal vein embolization
-
批准号:05671081
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1993
-
负责人:KINOSHITA Hiroaki
-
依托单位:
海外基金